REGENXBIO (RGNX) to Post Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect REGENXBIO to announce earnings of $0.12 per share and revenue of $97.6290 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The company had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $25.84 million. REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. On average, analysts expect REGENXBIO to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

REGENXBIO Trading Up 3.4%

Shares of RGNX opened at $10.30 on Wednesday. The firm has a market capitalization of $532.51 million, a P/E ratio of -1.84 and a beta of 0.94. The stock’s fifty day simple moving average is $9.78 and its 200 day simple moving average is $9.46. REGENXBIO has a twelve month low of $5.45 and a twelve month high of $16.19.

Insiders Place Their Bets

In related news, insider Steve Pakola sold 2,161 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total value of $29,476.04. Following the completion of the sale, the insider directly owned 213,009 shares in the company, valued at approximately $2,905,442.76. This represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 73,803 shares of company stock worth $886,937. 14.22% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Aquatic Capital Management LLC acquired a new stake in shares of REGENXBIO in the third quarter valued at about $37,000. Captrust Financial Advisors purchased a new stake in shares of REGENXBIO during the 2nd quarter valued at about $85,000. Prudential Financial Inc. acquired a new position in REGENXBIO during the 2nd quarter worth approximately $87,000. CANADA LIFE ASSURANCE Co lifted its position in REGENXBIO by 271.8% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 7,924 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in REGENXBIO in the 2nd quarter worth approximately $108,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

RGNX has been the subject of a number of research reports. Zacks Research downgraded REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Leerink Partners lifted their price objective on REGENXBIO from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of REGENXBIO in a report on Wednesday, July 1st. Finally, Barclays dropped their target price on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.